Please assess the completion status of the following clinical trial:

Trial Title: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of symptomatic macular PCV in the study eye~* A qualifying vision score at study entry~* A qualifying lesion size in the study eye at study entry~Exclusion Criteria:~* Active inflammation or infection in the study eye~* Uncontrolled intraocular pressure in the stuy eye~* Ocular condition in the study eye which may impact vision and confound study outcomes~* Prior treatment of the study eye with anti-VEGF therapy, verteporfin PDT, other laser and surgical interventions, intraocular corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab + vPDT (Type: EXPERIMENTAL): Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
- Ranibizumab monotherapy (Type: ACTIVE_COMPARATOR): Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).